降糖药物与非酒精性脂肪性肝病的相关研究进展

Research progress of hypoglycemic agents and non-alcoholic fatty liver disease

非酒精性脂肪性肝病(NAFLD)是与IR、肥胖和高脂血症密切相关的临床综合征。IR是T2DM和NAFLD共同的发病机制之一。一些降糖药物除降糖作用外还有控制体重、调节血脂和改善IR等特点,但有的本身具有药物性肝损害(DILI)。降糖药物是否对NAFLD产生影响尚无定论,本文就各类降糖药物和NAFLD的相关研究进展作一综述。

Non-alcoholic fatty liver disease（NAFLD）is a clinical syndrome closely associated with IR,obesity and hyperlipidemia.IR plays a role in both NAFLD and T2 DM pathogenesis.Some hypoglycemic agents can control body weight;regulate blood lipid and lower insulin resistance beside their anti-hyperglycemic effects.However,some of them can cause drug-induced liver injury（DILI）.Whether hypoglycemic agents have any effect on NAFLD was unknown.Here we summarize the research progress in a variety of hypoglycemic agents and NAFLD for reference.